601 related articles for article (PubMed ID: 34554329)
1. Risk of venous thromboembolism associated with Janus kinase inhibitors for rheumatoid arthritis: case presentation and literature review.
Mori S; Ogata F; Tsunoda R
Clin Rheumatol; 2021 Nov; 40(11):4457-4471. PubMed ID: 34554329
[TBL] [Abstract][Full Text] [Related]
2. Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data.
Mease P; Charles-Schoeman C; Cohen S; Fallon L; Woolcott J; Yun H; Kremer J; Greenberg J; Malley W; Onofrei A; Kanik KS; Graham D; Wang C; Connell C; Valdez H; Hauben M; Hung E; Madsen A; Jones TV; Curtis JR
Ann Rheum Dis; 2020 Nov; 79(11):1400-1413. PubMed ID: 32759265
[TBL] [Abstract][Full Text] [Related]
3. Crucial safety issues on Janus kinase inhibitors in rheumatoid arthritis might be associated with the lack of LDL-cholesterol management: a reasoned literature analysis.
Corrao S
Intern Emerg Med; 2023 Nov; 18(8):2157-2161. PubMed ID: 37898967
[TBL] [Abstract][Full Text] [Related]
4. Thromboembolism with Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis: How Real is the Risk?
Scott IC; Hider SL; Scott DL
Drug Saf; 2018 Jul; 41(7):645-653. PubMed ID: 29500799
[TBL] [Abstract][Full Text] [Related]
5. Safety of JAK inhibitors: focus on cardiovascular and thromboembolic events.
Atzeni F; Popa CD; Nucera V; Nurmohamed MT
Expert Rev Clin Immunol; 2022 Mar; 18(3):233-244. PubMed ID: 35129033
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular risks associated with Janus kinase inhibitors: peering outside the black box.
Misra DP; Pande G; Agarwal V
Clin Rheumatol; 2023 Feb; 42(2):621-632. PubMed ID: 36264400
[TBL] [Abstract][Full Text] [Related]
7. Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis.
Molander V; Bower H; Frisell T; Delcoigne B; Di Giuseppe D; Askling J;
Ann Rheum Dis; 2023 Feb; 82(2):189-197. PubMed ID: 36150749
[TBL] [Abstract][Full Text] [Related]
8. Venous Thromboembolism Risk With JAK Inhibitors: A Meta-Analysis.
Yates M; Mootoo A; Adas M; Bechman K; Rampes S; Patel V; Qureshi S; Cope AP; Norton S; Galloway JB
Arthritis Rheumatol; 2021 May; 73(5):779-788. PubMed ID: 33174384
[TBL] [Abstract][Full Text] [Related]
9. Comparative Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Receiving Tofacitinib Versus Those Receiving Tumor Necrosis Factor Inhibitors: An Observational Cohort Study.
Desai RJ; Pawar A; Weinblatt ME; Kim SC
Arthritis Rheumatol; 2019 Jun; 71(6):892-900. PubMed ID: 30552833
[TBL] [Abstract][Full Text] [Related]
10. JAK inhibitors and risk of major cardiovascular events or venous thromboembolism: a self-controlled case series study.
Gouverneur A; Avouac J; Prati C; Cracowski JL; Schaeverbeke T; Pariente A; Truchetet ME
Eur J Clin Pharmacol; 2022 Dec; 78(12):1981-1990. PubMed ID: 36284012
[TBL] [Abstract][Full Text] [Related]
11. Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors.
Verden A; Dimbil M; Kyle R; Overstreet B; Hoffman KB
Drug Saf; 2018 Apr; 41(4):357-361. PubMed ID: 29196988
[TBL] [Abstract][Full Text] [Related]
12. Risk of venous thromboembolism associated with tofacitinib in patients with rheumatoid arthritis: a population-based cohort study.
Desai RJ; Pawar A; Khosrow-Khavar F; Weinblatt ME; Kim SC
Rheumatology (Oxford); 2021 Dec; 61(1):121-130. PubMed ID: 33752237
[TBL] [Abstract][Full Text] [Related]
13. Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors.
Weitz JI; Szekanecz Z; Charles-Schoeman C; Vranic I; Sahin B; Paciga SA; Wang Z; Hyde C; Martin DA
RMD Open; 2022 Nov; 8(2):. PubMed ID: 36323490
[TBL] [Abstract][Full Text] [Related]
14. Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database.
Taylor PC; Takeuchi T; Burmester GR; Durez P; Smolen JS; Deberdt W; Issa M; Terres JR; Bello N; Winthrop KL
Ann Rheum Dis; 2022 Mar; 81(3):335-343. PubMed ID: 34706874
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis.
Taylor PC; Weinblatt ME; Burmester GR; Rooney TP; Witt S; Walls CD; Issa M; Salinas CA; Saifan C; Zhang X; Cardoso A; González-Gay MA; Takeuchi T
Arthritis Rheumatol; 2019 Jul; 71(7):1042-1055. PubMed ID: 30663869
[TBL] [Abstract][Full Text] [Related]
16. Comparative effectiveness and safety of non-tumour necrosis factor biologics and Janus kinase inhibitors in patients with active rheumatoid arthritis showing insufficient response to tumour necrosis factor inhibitors: A Bayesian network meta-analysis of randomized controlled trials.
Sung YK; Lee YH
J Clin Pharm Ther; 2021 Aug; 46(4):984-992. PubMed ID: 33600008
[TBL] [Abstract][Full Text] [Related]
17. Incidence of inpatient venous thromboembolism in treated patients with rheumatoid arthritis and the association with switching biologic or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) in the real-world setting.
Liang H; Danwada R; Guo D; Curtis JR; Kilpatrick RD; Hendrickson B; Islam SS
RMD Open; 2019; 5(2):e001013. PubMed ID: 31673413
[TBL] [Abstract][Full Text] [Related]
18. The risk and trend of pulmonary embolism and deep vein thrombosis in rheumatoid arthritis: a general population-based study.
Li L; Lu N; Avina-Galindo AM; Zheng Y; Lacaille D; Esdaile JM; Choi HK; Aviña-Zubieta JA
Rheumatology (Oxford); 2021 Jan; 60(1):188-195. PubMed ID: 32617563
[TBL] [Abstract][Full Text] [Related]
19. A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19.
Bieber T; Feist E; Irvine AD; Harigai M; Haladyj E; Ball S; Deberdt W; Issa M; Grond S; Taylor PC
Adv Ther; 2022 Nov; 39(11):4910-4960. PubMed ID: 36063279
[TBL] [Abstract][Full Text] [Related]
20. Risk of venous thromboembolism in Korean patients with rheumatoid arthritis treated with Janus kinase inhibitors: A nationwide population-based study.
Song YJ; Cho SK; Kim JY; You SH; Kim H; Jung SY; Sung YK
Semin Arthritis Rheum; 2023 Aug; 61():152214. PubMed ID: 37172496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]